1 BACKGROUND Nasopharyngeal carcinoma(NPC)is a unique head and neck malignancy prevalent in East Asia[1].It is highly malignant,with the non-keratinizing pathological subtype constituting approximately 95%of NPC cases...1 BACKGROUND Nasopharyngeal carcinoma(NPC)is a unique head and neck malignancy prevalent in East Asia[1].It is highly malignant,with the non-keratinizing pathological subtype constituting approximately 95%of NPC cases in endemic areas.Chemotherapy in combination with radiotherapy is recommended for locoregionally advanced NPC(LANPC),especially in subgroups at higher risk of distant metastasis(e.g.,N2-3 vs.N0-1 diseases,high vs.low plasma Epstein-Barr virus[EBV]DNA copy number)[2,3].Concurrent chemoradiotherapy with or without induction chemotherapy is considered the backbone of the current chemoradiotherapy strategies for NPC[2,3].Nevertheless,although complete clinical remission could be achieved in more than 90%of patients after definitive chemoradiotherapy,about 20%-30%of patients will have disease recurrence subsequently[4,5],which might be caused minimal residual disease(MRD),either at locoregional or distant sites[6,7].Thus,adjuvant therapy is needed to improve tumor control.展开更多
基金the National Natural Science Foundation of China(82172749)the Natural Science Foundation of Guangdong Province(2021B1515020010)the Fundamental Research Funds for the Central Universities,Sun Yat-sen University(22ykqb14).
文摘1 BACKGROUND Nasopharyngeal carcinoma(NPC)is a unique head and neck malignancy prevalent in East Asia[1].It is highly malignant,with the non-keratinizing pathological subtype constituting approximately 95%of NPC cases in endemic areas.Chemotherapy in combination with radiotherapy is recommended for locoregionally advanced NPC(LANPC),especially in subgroups at higher risk of distant metastasis(e.g.,N2-3 vs.N0-1 diseases,high vs.low plasma Epstein-Barr virus[EBV]DNA copy number)[2,3].Concurrent chemoradiotherapy with or without induction chemotherapy is considered the backbone of the current chemoradiotherapy strategies for NPC[2,3].Nevertheless,although complete clinical remission could be achieved in more than 90%of patients after definitive chemoradiotherapy,about 20%-30%of patients will have disease recurrence subsequently[4,5],which might be caused minimal residual disease(MRD),either at locoregional or distant sites[6,7].Thus,adjuvant therapy is needed to improve tumor control.
